Celiac Disease: Advances in Treatment via Gluten Modification

Samantha Stoven; Joseph A. Murray; Eric Marietta

doi:10.1016/j.cgh.2012.06.005

Celiac Disease: Advances in Treatment via Gluten Modification

Samantha Stoven, Joseph A. Murray, Eric Marietta

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically susceptible individuals carrying the prerequisite genetic markers HLA DQ2 or DQ8. These genetic markers are present in approximately 30% of the population, and the worldwide prevalence of CD is estimated to be approximately 1%-2%. Currently a gluten-free diet is the only treatment for CD, but novel therapies aimed at gluten modification are underway. This review will discuss gluten-based therapies including wheat alternatives and wheat selection, enzymatic alteration of wheat, oral enzyme supplements, and polymeric binders as exciting new therapies for treatment of CD.

Original language	English (US)
Pages (from-to)	859-862
Number of pages	4
Journal	Clinical Gastroenterology and Hepatology
Volume	10
Issue number	8
DOIs	https://doi.org/10.1016/j.cgh.2012.06.005
State	Published - Aug 2012

Keywords

Autoimmune
Celiac
Gluten
Therapies
Treatment

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/j.cgh.2012.06.005

Cite this

@article{e117b3b3a2d247f8b07b28693a6481a3,

title = "Celiac Disease: Advances in Treatment via Gluten Modification",

abstract = "Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically susceptible individuals carrying the prerequisite genetic markers HLA DQ2 or DQ8. These genetic markers are present in approximately 30% of the population, and the worldwide prevalence of CD is estimated to be approximately 1%-2%. Currently a gluten-free diet is the only treatment for CD, but novel therapies aimed at gluten modification are underway. This review will discuss gluten-based therapies including wheat alternatives and wheat selection, enzymatic alteration of wheat, oral enzyme supplements, and polymeric binders as exciting new therapies for treatment of CD.",

keywords = "Autoimmune, Celiac, Gluten, Therapies, Treatment",

author = "Samantha Stoven and Murray, {Joseph A.} and Eric Marietta",

year = "2012",

month = aug,

doi = "10.1016/j.cgh.2012.06.005",

language = "English (US)",

volume = "10",

pages = "859--862",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "8",

}

TY - JOUR

T1 - Celiac Disease

T2 - Advances in Treatment via Gluten Modification

AU - Stoven, Samantha

AU - Murray, Joseph A.

AU - Marietta, Eric

PY - 2012/8

Y1 - 2012/8

N2 - Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically susceptible individuals carrying the prerequisite genetic markers HLA DQ2 or DQ8. These genetic markers are present in approximately 30% of the population, and the worldwide prevalence of CD is estimated to be approximately 1%-2%. Currently a gluten-free diet is the only treatment for CD, but novel therapies aimed at gluten modification are underway. This review will discuss gluten-based therapies including wheat alternatives and wheat selection, enzymatic alteration of wheat, oral enzyme supplements, and polymeric binders as exciting new therapies for treatment of CD.

AB - Celiac disease (CD) is an autoimmune enteropathy that occurs in genetically susceptible individuals carrying the prerequisite genetic markers HLA DQ2 or DQ8. These genetic markers are present in approximately 30% of the population, and the worldwide prevalence of CD is estimated to be approximately 1%-2%. Currently a gluten-free diet is the only treatment for CD, but novel therapies aimed at gluten modification are underway. This review will discuss gluten-based therapies including wheat alternatives and wheat selection, enzymatic alteration of wheat, oral enzyme supplements, and polymeric binders as exciting new therapies for treatment of CD.

KW - Autoimmune

KW - Celiac

KW - Gluten

KW - Therapies

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84864109994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864109994&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2012.06.005

DO - 10.1016/j.cgh.2012.06.005

M3 - Article

C2 - 22728383

AN - SCOPUS:84864109994

SN - 1542-3565

VL - 10

SP - 859

EP - 862

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 8

ER -

Celiac Disease: Advances in Treatment via Gluten Modification

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this